IL236456A0 - Targeted therapeutics - Google Patents

Targeted therapeutics

Info

Publication number
IL236456A0
IL236456A0 IL236456A IL23645614A IL236456A0 IL 236456 A0 IL236456 A0 IL 236456A0 IL 236456 A IL236456 A IL 236456A IL 23645614 A IL23645614 A IL 23645614A IL 236456 A0 IL236456 A0 IL 236456A0
Authority
IL
Israel
Prior art keywords
targeted therapeutics
therapeutics
targeted
Prior art date
Application number
IL236456A
Other languages
Hebrew (he)
Other versions
IL236456B (en
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of IL236456A0 publication Critical patent/IL236456A0/en
Publication of IL236456B publication Critical patent/IL236456B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
IL236456A 2012-06-25 2014-12-25 Compositions comprising therapeutically active agents conjugated to heparin binding peptide IL236456B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261663679P 2012-06-25 2012-06-25
PCT/US2013/047550 WO2014004465A1 (en) 2012-06-25 2013-06-25 Targeted therapeutics

Publications (2)

Publication Number Publication Date
IL236456A0 true IL236456A0 (en) 2015-02-26
IL236456B IL236456B (en) 2018-02-28

Family

ID=49783785

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236456A IL236456B (en) 2012-06-25 2014-12-25 Compositions comprising therapeutically active agents conjugated to heparin binding peptide

Country Status (12)

Country Link
US (2) US9421245B2 (en)
EP (2) EP2864360B1 (en)
JP (1) JP5918909B2 (en)
CN (1) CN104619727B (en)
CA (1) CA2877886A1 (en)
DK (1) DK2864360T3 (en)
ES (1) ES2651113T3 (en)
HK (1) HK1209762A1 (en)
HU (1) HUE035607T2 (en)
IL (1) IL236456B (en)
PT (1) PT2864360T (en)
WO (1) WO2014004465A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA38369B1 (en) 2013-03-08 2018-10-31 Novartis Ag Peptides and compositions for the treatment of a lesion of the joint
JO3564B1 (en) 2013-03-08 2020-07-05 Novartis Ag Peptides and compositions for treatment of joint damage
WO2018170480A1 (en) * 2017-03-16 2018-09-20 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
GB201322396D0 (en) * 2013-12-18 2014-02-05 Univ Nottingham Transduction
WO2016076102A1 (en) 2014-11-14 2016-05-19 株式会社リジェネシスサイエンス Method for serum-free culture of cartilage cells and serum-free culture medium
IL282614B2 (en) 2015-02-06 2024-02-01 Cell Idx Inc Antigen-coupled immunoreagents
ES2927067T3 (en) * 2015-03-03 2022-11-02 Radius Health Inc Abaloparatide combined with alendronate for the reduction of non-vertebral bone fractures
CN107849151B (en) * 2015-07-15 2022-05-24 德益阳光生物技术（北京）有限责任公司 Fusion polypeptides and methods of use
JP7044373B2 (en) 2015-07-15 2022-03-30 ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー Nuclease-independent targeted gene editing platform and its uses
EP3347035A4 (en) 2015-09-09 2019-05-01 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
US20170087221A1 (en) * 2015-09-30 2017-03-30 Elwha Llc Nitric oxide-modulating bone-targeting complexes
CN105504069B (en) * 2016-01-28 2019-12-13 中国人民解放军第三军医大学第一附属医院 Fusion peptide for promoting osteoblast adhesion and osteogenic differentiation and preparation method and application thereof
US20190265235A1 (en) * 2016-07-18 2019-08-29 Cell Idx, Inc. Reagent compounds, compositions, kits, and methods for amplified assays
GB201615989D0 (en) * 2016-09-20 2016-11-02 Imp Innovations Ltd Drug Delivery
WO2018057522A1 (en) * 2016-09-20 2018-03-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface
WO2018165867A1 (en) * 2017-03-14 2018-09-20 浙江日升昌药业有限公司 Tumor-targeting polypeptide, preparation method and application thereof
WO2018213934A1 (en) 2017-05-26 2018-11-29 The Governors Of The University Of Alberta Self-assembling peptide for activating human mast cells
CN107375910B (en) * 2017-07-12 2020-03-24 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 Application of PTHrP in preparation of medicine for treating male hypogonadism syndrome
AU2018301716A1 (en) 2017-07-14 2020-02-13 The Regents Of The University Of California Novel methods of predicting transplant rejection risk
US11529389B2 (en) 2018-03-09 2022-12-20 University of Pittsburgh—of the Commonwealth System of Higher Education Delivering biological drugs to tissues
EP3768296B1 (en) * 2018-03-23 2023-09-06 Arch Biosurgery, Inc. Sap and peptidomimetics for treatment of eye disease
US20210163556A1 (en) * 2018-04-06 2021-06-03 Northwestern University Bdnf mimetic peptide amphiphiles
WO2019200326A1 (en) 2018-04-13 2019-10-17 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
CN108925783B (en) * 2018-07-23 2021-09-21 浙江大学 Application of bemisia tabaci MANF gene or expressed protein thereof as target in preparation of drug for preventing and treating bemisia tabaci
TW202027794A (en) 2018-10-03 2020-08-01 瑞士商諾華公司 Sustained delivery of angiopoetin-like 3 polypeptides
US20220106584A1 (en) 2019-01-14 2022-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
JP6873436B2 (en) * 2019-05-17 2021-05-19 学校法人大阪医科薬科大学 Pharmaceutical composition for the treatment of joint diseases and its manufacturing method
CN110237238A (en) * 2019-08-02 2019-09-17 山东省眼科研究所 MANF is promoting the application in corneal injury reparation
CN112646042A (en) * 2019-10-10 2021-04-13 陕西麦科奥特科技有限公司 Active polypeptide compounds
EP3838912A1 (en) * 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
US20230235315A1 (en) 2020-07-10 2023-07-27 Horizon Discovery Limited Method for producing genetically modified cells
CN112587654B (en) * 2020-12-18 2022-10-14 安徽医科大学 Application of mesencephalon astrocyte-derived neurotrophic factor in treatment of ulcerative colitis
CN113024675A (en) * 2020-12-29 2021-06-25 山东第一医科大学(山东省医学科学院) HB-NC4 recombinant protein, preparation method and application thereof
EP4274893A1 (en) 2021-01-05 2023-11-15 Horizon Discovery Limited Method for producing genetically modified cells
WO2022173926A1 (en) * 2021-02-10 2022-08-18 3-D Matrix, Ltd. Pharmaceutical composition containing specific self-assembling peptide rada16 for treating or preventing lower gastrointestinal diseases such as inflammatory bowel disease
CN113244413B (en) * 2021-06-28 2021-10-26 深圳市瑞吉生物科技有限公司 mRNA (messenger ribonucleic acid) dosage form osteoarthritis pharmaceutical preparation as well as preparation method and application thereof
CN115887619B (en) * 2021-09-30 2024-03-26 四川大学 Application of astrocyte-derived neurotrophic factor in midbrain and pharmaceutical composition

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
IT1190891B (en) 1982-06-24 1988-02-24 Anic Spa METHOD FOR SOLID PHASE SYNTHESIS OF RETROINVERTED POLYPEPTIDES
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
EP0545999B1 (en) 1990-08-20 1997-06-04 Novo Nordisk A/S Process for the preparation of biologically active IGF-1 using IGF-1 having an amino-terminal extension
ATE447016T1 (en) 1991-01-21 2009-11-15 Elan Pharm Inc TEST AND MODEL FOR ALZHEIMERS DISEASE
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
GB9207732D0 (en) 1992-04-06 1992-05-27 Isis Innovation Wound repair
KR950702839A (en) 1992-08-27 1995-08-23 스티븐 딕 Retro, Inverso-, and Retro-Inverso Synthetic Peptide Analogues (RETRO-, INVERSO-, AND RETRO-INVERSO SYNTHETIC PEPTIDE ANALOGUES)
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5670483A (en) 1992-12-28 1997-09-23 Massachusetts Insititute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
JP3545403B2 (en) 1993-04-22 2004-07-21 スカイファルマ インコーポレイテッド Cyclodextrin liposomes encapsulating pharmaceutical compounds and methods of use
DK0729351T3 (en) 1993-11-16 2000-10-16 Skyepharma Inc Vesicles with regulated release of active substances
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
WO1996008274A2 (en) * 1994-09-13 1996-03-21 Prizm Pharmaceuticals, Inc. Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
EP0920490A2 (en) 1996-07-25 1999-06-09 Genzyme Corporation Chondrocyte media formulations and culture procedures
EP0971747B1 (en) 1996-10-28 2005-12-28 Amersham Health AS Contrast agents
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6337072B1 (en) * 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AUPP298498A0 (en) 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US6855801B1 (en) * 1999-02-02 2005-02-15 Thomas Jefferson University Peptides modulating activities of heparin other glycosaminoglycans or proteoglycans
EP1253948A2 (en) * 2000-02-11 2002-11-06 Genvec, Inc. Gene therapy for treating ocular-related disorders
GB0027328D0 (en) 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
US7060681B2 (en) * 2001-07-20 2006-06-13 Ecole Polytechnique Federale De Lausanne (Epfl) Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids
CA2455830C (en) * 2001-07-31 2012-10-09 Wayne State University Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
MXPA04006021A (en) * 2001-12-18 2005-08-19 Eth Zuerich Growth factor modified protein matrices for tissue engineering.
WO2004018499A2 (en) 2002-08-20 2004-03-04 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
WO2005014619A2 (en) * 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
US8039258B2 (en) 2004-09-28 2011-10-18 Ethicon, Inc. Tissue-engineering scaffolds containing self-assembled-peptide hydrogels
EP1812030A4 (en) * 2004-10-14 2009-01-14 Sopherion Therapeutics Inc Anti-angiogenic peptides and methods of use thereof
US7399831B2 (en) 2004-10-25 2008-07-15 The Brigham And Women's Hospital, Inc. Targeted delivery of biological factors using self-assembling peptide nanofibers
JP2008526749A (en) 2005-01-04 2008-07-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド Sustained release delivery of PDGF using self-assembling peptide nanofibers
US7930958B2 (en) 2005-07-14 2011-04-26 Provo Craft And Novelty, Inc. Blade housing for electronic cutting apparatus
US8486621B2 (en) * 2005-08-11 2013-07-16 Cornell Research Foundation, Inc. Nucleic acid-based matrixes
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
JP2009526045A (en) * 2006-02-10 2009-07-16 デルマゲン アクティエボラーグ Novel antimicrobial peptides and uses thereof
WO2008002661A2 (en) 2006-06-28 2008-01-03 The Board Of Trustees Of The Leland Stanford Junior University Fusion protein constructs
AR062522A1 (en) * 2006-08-25 2008-11-12 Ares Trading Sa TREATMENT OF DISORDERS IN CARTILAGOS
US9187517B2 (en) * 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
US8772471B2 (en) 2007-01-26 2014-07-08 Industry-University Cooperation Foundation Hanyang University Targeted delivery of siRNA
IN2012DN00572A (en) 2009-07-14 2015-06-12 Scripps Research Inst
WO2011146902A1 (en) * 2010-05-21 2011-11-24 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
EP2575909B1 (en) 2010-06-03 2020-01-15 Technology Innovation Momentum Fund (Israel) Limited Partnership Malleable hydrogel hybrids made of self-assembled peptides and biocompatible polymers and uses thereof
US8546338B2 (en) 2010-12-08 2013-10-01 Johnson & Johnson Consumer Companies, Inc. Self-assembling hydrogels based on dicephalic peptide amphiphiles
US9072706B2 (en) * 2010-12-14 2015-07-07 University Of Rochester Chimeric fibronectin matrix mimetics and uses therof
ES2676499T3 (en) 2011-04-13 2018-07-20 Bristol-Myers Squibb Company Fc fusion proteins comprising new linkers or arrangements

Also Published As

Publication number Publication date
HUE035607T2 (en) 2018-05-28
WO2014004465A1 (en) 2014-01-03
EP2864360A1 (en) 2015-04-29
PT2864360T (en) 2018-01-05
HK1209762A1 (en) 2016-04-08
DK2864360T3 (en) 2017-12-18
ES2651113T3 (en) 2018-01-24
JP5918909B2 (en) 2016-05-18
CA2877886A1 (en) 2014-01-03
US20150182596A1 (en) 2015-07-02
EP2864360B1 (en) 2017-09-06
US9421245B2 (en) 2016-08-23
JP2015522590A (en) 2015-08-06
IL236456B (en) 2018-02-28
CN104619727A (en) 2015-05-13
US20170015726A1 (en) 2017-01-19
CN104619727B (en) 2019-04-05
EP3369747A1 (en) 2018-09-05
EP2864360A4 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
IL277912A (en) Targeted therapeutics
HK1209762A1 (en) Targeted therapeutics
HK1202051A1 (en) Erythrocyte-binding therapeutics
DK3327112T3 (en) Agse-deficient stamme
EP2754580A4 (en) Dumptruck
EP2935220A4 (en) Peri-carbinols
EP2920142A4 (en) Methanofullerenes
GB2501004B (en) Two piece drysuit
EP2812698A4 (en) Dual-acceptor time-resolved-fret
GB201903206D0 (en) n
EP2920157A4 (en) Di-macrocycles
EP2873363A4 (en) Diopsimeter
GB2500883B (en) Improved saw-horse
EP2834250A4 (en) Lithiumsilicate
ZA201305187B (en) Improved brattice
AU345893S (en) Treehouse
GB201207541D0 (en) Ecopouffe
GB201202887D0 (en) TV-audio
GB201202916D0 (en) E-Space
GB201202912D0 (en) Swingdoctor
GB201202648D0 (en) Xstyler
GB201202655D0 (en) Ecogaz
GB201202382D0 (en) Flexfix
GB201202303D0 (en) Myhealthbadge
GB201202208D0 (en) Easomark

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed